TG Therapeutics to Participate in the Cantor Global Healthcare Conference
Rhea-AI Summary
TG Therapeutics (NASDAQ:TGTX) announced its participation in the upcoming Cantor Global Healthcare Conference in New York, NY from September 3-5, 2025. Michael S. Weiss, the company's Chairman and CEO, will engage in a fireside chat on Wednesday, September 3, 2025, at 10:20am ET.
Investors can access a live webcast of the presentation through the Events page in the Investors & Media section of TG Therapeutics' website.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, TGTX gained 1.37%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Fireside chat scheduled for Wednesday, September 3, 2025, at 10:20am ET
NEW YORK, Aug. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Cantor Global Healthcare Conference, being held in New York, NY on September 3 - 5, 2025. The fireside chat is scheduled to take place on Wednesday, September 3, 2025, at 10:20am ET.
A live webcast of the fireside chat will be available on the Events page, located within the Investors & Media section, of the Company’s website at http://ir.tgtherapeutics.com/events.
ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval by the European Commission (EC) in Europe, the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom, Swissmedic in Switzerland, and Australia’s Therapeutic Goods Administration (TGA) for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn.
BRIUMVI® is a registered trademark of TG Therapeutics, Inc.
CONTACT:
Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4
Media Relations:
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6
FAQ
When is TG Therapeutics (TGTX) presenting at the Cantor Global Healthcare Conference 2025?
Who will represent TG Therapeutics at the Cantor Global Healthcare Conference?
Where can I watch TG Therapeutics' presentation at the Cantor conference?
Where is the Cantor Global Healthcare Conference 2025 being held?
